IL236261A0 - Complexes of cytomegalovirus proteins - Google Patents
Complexes of cytomegalovirus proteinsInfo
- Publication number
- IL236261A0 IL236261A0 IL236261A IL23626114A IL236261A0 IL 236261 A0 IL236261 A0 IL 236261A0 IL 236261 A IL236261 A IL 236261A IL 23626114 A IL23626114 A IL 23626114A IL 236261 A0 IL236261 A0 IL 236261A0
- Authority
- IL
- Israel
- Prior art keywords
- protein complexes
- cytomegalovirus protein
- cytomegalovirus
- complexes
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668975P | 2012-07-06 | 2012-07-06 | |
| US201361770257P | 2013-02-27 | 2013-02-27 | |
| PCT/EP2013/063750 WO2014005959A1 (en) | 2012-07-06 | 2013-06-29 | Complexes of cytomegalovirus proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL236261A0 true IL236261A0 (en) | 2015-02-26 |
Family
ID=48783208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL236261A IL236261A0 (en) | 2012-07-06 | 2014-12-15 | Complexes of cytomegalovirus proteins |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9683022B2 (enExample) |
| EP (1) | EP2869843B1 (enExample) |
| JP (3) | JP2015522581A (enExample) |
| KR (1) | KR20150031322A (enExample) |
| CN (1) | CN104853771A (enExample) |
| AU (1) | AU2013286093B2 (enExample) |
| CA (1) | CA2878344A1 (enExample) |
| ES (1) | ES2753138T3 (enExample) |
| GB (1) | GB2513768B (enExample) |
| HK (1) | HK1210037A1 (enExample) |
| IL (1) | IL236261A0 (enExample) |
| IN (1) | IN2014KN02929A (enExample) |
| MX (2) | MX355469B (enExample) |
| RU (1) | RU2015103891A (enExample) |
| SG (1) | SG11201408328VA (enExample) |
| WO (1) | WO2014005959A1 (enExample) |
| ZA (1) | ZA201409364B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013286093B2 (en) | 2012-07-06 | 2018-01-04 | Novartis Ag | Complexes of cytomegalovirus proteins |
| CA2879577C (en) | 2012-07-27 | 2021-08-03 | City Of Hope | An mva vaccine for delivery of a ul128 complex and preventing cmv infection |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| RS61993B1 (sr) * | 2013-12-03 | 2021-07-30 | Hookipa Biotech Gmbh | Cmv vakcine |
| EP3134117A1 (en) * | 2014-04-23 | 2017-03-01 | Institute for Research in Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| WO2015165480A1 (en) * | 2014-04-30 | 2015-11-05 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| MX2016014660A (es) * | 2014-05-08 | 2017-02-28 | Pfizer | Medios y metodos para el tratamiento de cmv. |
| EP3015475A1 (en) * | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
| EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| EP3047856A1 (en) * | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv antigens and uses thereof |
| EP3347045A4 (en) | 2015-09-10 | 2019-08-28 | City of Hope | MVA-GH / GL-PC VACCINATED ANTIBODIES FOR NEUTRALIZING THE INFECTIOSITY OF HUMAN CYTOMEGALOVIRUS AND METHOD THEREFOR |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| US10022436B2 (en) | 2016-01-11 | 2018-07-17 | Verndari, Inc. | Microneedle compositions and methods of using same |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| CA3050914A1 (en) * | 2017-01-27 | 2018-08-02 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccine compositions of herpesvirus envelope protein combinations to induce immune response |
| EP3606942B1 (en) | 2017-04-04 | 2025-06-11 | University of Washington | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use |
| EP3612550B1 (en) | 2017-04-19 | 2025-06-18 | GlaxoSmithKline Biologicals S.A. | Modified cytomegalovirus proteins and stabilized complexes |
| EP3658581A1 (en) * | 2017-07-24 | 2020-06-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies and peptides to treat hcmv related diseases |
| WO2019023566A1 (en) * | 2017-07-28 | 2019-01-31 | Janssen Vaccines & Prevention B.V. | METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP |
| KR20200051778A (ko) * | 2017-09-13 | 2020-05-13 | 사노피 파스퇴르 | 인간 시토메갈로바이러스 면역원성 조성물 |
| CN112088014B (zh) * | 2018-02-28 | 2026-03-24 | 华盛顿大学 | 自组装纳米结构疫苗 |
| US12433944B2 (en) | 2018-05-04 | 2025-10-07 | SpyBiotech Limited | Vaccine composition |
| WO2020079586A1 (en) * | 2018-10-17 | 2020-04-23 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| US12290560B2 (en) | 2018-12-10 | 2025-05-06 | Km Biologics Co., Ltd. | Vaccine for preventing or treating congenital infection with cytomegalovirus |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| EP4004018A1 (en) | 2019-07-24 | 2022-06-01 | GlaxoSmithKline Biologicals SA | Modified human cytomegalovirus proteins |
| JP7271794B2 (ja) | 2020-06-09 | 2023-05-11 | Ｋｍバイオロジクス株式会社 | サイトメガロウイルスのｇＢとペンタマーとの融合タンパク質及び該融合タンパク質を含むワクチン |
| TWI871709B (zh) | 2020-06-21 | 2025-02-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| KR20230097028A (ko) | 2020-10-28 | 2023-06-30 | 사노피 파스퇴르 | Tlr4 효현제를 함유하는 리포좀, 이의 제조 및 용도 |
| US20240299587A1 (en) * | 2021-02-24 | 2024-09-12 | Pfizer Inc. | Novel druggable regions in the human cytomegalovirus glycoprotein b polypeptide and methods of use thereof |
| US20250101067A1 (en) | 2022-01-28 | 2025-03-27 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68929402T2 (de) | 1988-12-22 | 2002-12-05 | Genentech, Inc. | Verfahren zur herstellung von wasserlöslichen polypeptiden |
| KR920701453A (ko) | 1989-03-17 | 1992-08-11 | 미리엄 디. 멕코나헤이 | 유전자발현의 외부조절 |
| JPH06501845A (ja) | 1990-08-02 | 1994-03-03 | カイロン コーポレイション | バキュロウイルス―昆虫細胞発現システムを用いたヒトｃｍｖ糖タンパク質―ｈの発現 |
| US5474914A (en) | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
| US5362865A (en) | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
| US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
| US5815900A (en) | 1995-03-06 | 1998-10-06 | Matsushita Electric Industrial Co., Ltd. | Method of manufacturing a surface acoustic wave module |
| WO2004076645A2 (en) * | 2003-02-27 | 2004-09-10 | University Of Massachusetts | Compositions and methods for cytomegalovirus treatment |
| US7704510B2 (en) | 2006-06-07 | 2010-04-27 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| US7947274B2 (en) * | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
| US9439960B2 (en) | 2007-10-10 | 2016-09-13 | The Trustees Of Princeton University | Cytomegalovirus vaccines and methods of production |
| US9950062B2 (en) | 2009-09-02 | 2018-04-24 | Glaxosmithkline Biologicals Sa | Compounds and compositions as TLR activity modulators |
| US9089537B2 (en) * | 2010-02-26 | 2015-07-28 | The Trustees Of The University Of Pennslyvania | Subunit vaccines for herpes viruses and methods of use |
| CN103153284B (zh) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| CA2804591C (en) | 2010-07-06 | 2019-01-22 | Novartis Ag | Cationic oil-in-water emulsions |
| WO2012015211A2 (ko) | 2010-07-30 | 2012-02-02 | 주식회사종근당 | 사이클로스포린 에이 함유 점안제 조성물 |
| EP2614072A4 (en) * | 2010-09-09 | 2014-03-19 | Univ Virginia Commonwealth | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| KR102266691B1 (ko) * | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| CA2826199A1 (en) | 2011-01-31 | 2012-08-09 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof |
| US9636410B2 (en) * | 2011-07-06 | 2017-05-02 | Glaxosmithkline Biologicals Sa | Cationic oil-in-water emulsions |
| US11058762B2 (en) | 2011-07-06 | 2021-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| PT2750707T (pt) * | 2011-08-31 | 2019-01-23 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para distribuição de arn que codifica imunogénio |
| AU2013286093B2 (en) | 2012-07-06 | 2018-01-04 | Novartis Ag | Complexes of cytomegalovirus proteins |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
-
2013
- 2013-06-29 AU AU2013286093A patent/AU2013286093B2/en not_active Ceased
- 2013-06-29 JP JP2015519155A patent/JP2015522581A/ja active Pending
- 2013-06-29 CN CN201380036145.0A patent/CN104853771A/zh active Pending
- 2013-06-29 CA CA2878344A patent/CA2878344A1/en not_active Abandoned
- 2013-06-29 ES ES13736518T patent/ES2753138T3/es active Active
- 2013-06-29 WO PCT/EP2013/063750 patent/WO2014005959A1/en not_active Ceased
- 2013-06-29 SG SG11201408328VA patent/SG11201408328VA/en unknown
- 2013-06-29 RU RU2015103891A patent/RU2015103891A/ru not_active Application Discontinuation
- 2013-06-29 US US14/410,461 patent/US9683022B2/en active Active
- 2013-06-29 MX MX2014015496A patent/MX355469B/es active IP Right Grant
- 2013-06-29 GB GB1413863.0A patent/GB2513768B/en active Active
- 2013-06-29 HK HK15110880.5A patent/HK1210037A1/xx unknown
- 2013-06-29 KR KR1020157002267A patent/KR20150031322A/ko not_active Withdrawn
- 2013-06-29 MX MX2018000675A patent/MX378747B/es unknown
- 2013-06-29 IN IN2929KON2014 patent/IN2014KN02929A/en unknown
- 2013-06-29 EP EP13736518.5A patent/EP2869843B1/en active Active
-
2014
- 2014-12-15 IL IL236261A patent/IL236261A0/en unknown
- 2014-12-18 ZA ZA2014/09364A patent/ZA201409364B/en unknown
-
2017
- 2017-05-16 US US15/596,066 patent/US10287322B2/en active Active
- 2017-08-01 JP JP2017149179A patent/JP2017192400A/ja active Pending
- 2017-08-01 JP JP2017149178A patent/JP2017192399A/ja active Pending
-
2019
- 2019-03-25 US US16/363,127 patent/US20190211064A1/en not_active Abandoned
-
2021
- 2021-12-15 US US17/551,867 patent/US20220106364A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014005959A1 (en) | 2014-01-09 |
| IN2014KN02929A (enExample) | 2015-05-08 |
| EP2869843A1 (en) | 2015-05-13 |
| CA2878344A1 (en) | 2014-01-09 |
| MX378747B (es) | 2025-03-10 |
| SG11201408328VA (en) | 2015-02-27 |
| EP2869843B1 (en) | 2019-08-07 |
| KR20150031322A (ko) | 2015-03-23 |
| MX2014015496A (es) | 2015-03-06 |
| JP2017192400A (ja) | 2017-10-26 |
| CN104853771A (zh) | 2015-08-19 |
| AU2013286093B2 (en) | 2018-01-04 |
| US10287322B2 (en) | 2019-05-14 |
| HK1210037A1 (en) | 2016-04-15 |
| MX355469B (es) | 2018-04-19 |
| RU2015103891A (ru) | 2016-08-27 |
| GB2513768B (en) | 2015-04-15 |
| US20190211064A1 (en) | 2019-07-11 |
| US20170320916A1 (en) | 2017-11-09 |
| ZA201409364B (en) | 2017-08-30 |
| AU2013286093A1 (en) | 2015-02-12 |
| US20160159864A1 (en) | 2016-06-09 |
| ES2753138T3 (es) | 2020-04-07 |
| JP2017192399A (ja) | 2017-10-26 |
| JP2015522581A (ja) | 2015-08-06 |
| GB201413863D0 (en) | 2014-09-17 |
| US20220106364A1 (en) | 2022-04-07 |
| US9683022B2 (en) | 2017-06-20 |
| GB2513768A (en) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20230011I1 (fi) | Farisimabi | |
| ZA201409364B (en) | Complexes of cytomegalovirus proteins | |
| UA24760S (uk) | Шрифт | |
| PT2814965T (pt) | Proteínas pesticidas manipuladas | |
| EP2914254A4 (en) | COMBINATION THERAPIES | |
| CL2014002180A1 (es) | Peptidos antomicrobianos | |
| EP2912953A4 (en) | MACARONI | |
| BR112014029129A2 (pt) | manipulação de proteínas | |
| ES1077199Y (es) | Vestido | |
| UA25745S (uk) | Зупинковий комплекс | |
| ES1078139Y (es) | Conjunto recargador | |
| EP2937362A4 (en) | RECOMBINANT PROTEIN | |
| TH1401005210B (th) | ชิ้นส่วนประกอบซ้อนทับ | |
| UA23806S (uk) | Літак | |
| UA23855S (uk) | Літак | |
| UA23749S (uk) | Літак | |
| BR302012006404S1 (pt) | Configuração aplicada em sandália | |
| BR302012006377S1 (pt) | Configuração aplicada em sandália | |
| BR302012006231S1 (pt) | Configuração aplicada em sandália | |
| BR302012005733S1 (pt) | Configuração aplicada em sandália | |
| BR302012005577S1 (pt) | Configuração aplicada em chinelo | |
| BR302012005192S1 (pt) | Configuração aplicada em sandália | |
| BR302012005191S1 (pt) | Configuração aplicada em chinelo | |
| BR302012005101S1 (pt) | Configuracao aplicada em sandalia | |
| BR302012005108S1 (pt) | Configuracao aplicada em sandália |